PRKACA and breast cancer: Protein kinase cAMP-activated catalytic subunit alpha (PRKACA)-mediated phosphorylation of MORC2 on T582 abrogates CMA-mediated degradation of MORC2, leading to endocrine resistance of breast cancer cells [124].